Abstracts tagged "Mortality"

Abstract Number: 0106 • ACR Convergence 2021
COVID-19 Mortality and Hospitalization Risk in Patients with Rheumatic Diseases: A Single Center Retrospective Cohort Study
Mousa Albalwi, Ben Brintz, Srinivasan Beddhu, Guo Wei and Julie Thomas, University of Utah, Salt Lake City, UT
Background/Purpose: Following SARS-CoV-2 infection, patients with rheumatic diseases seem to have similar or slightly poorer outcomes compared with those without rheumatic disease. However, robust data…
Abstract Number: 0779 • ACR Convergence 2021
Predictors of Mortality in a Series of 1528 Brazilian Childhood-onset Systemic Lupus Erythematosus Patients
Ana Paula Sakamoto¹, Clovis Artur Silva², Aline Islabão³, Glaucia Novak⁴, Beatriz Molinari⁴, Rosa Pereira², Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Melissa Fraga⁶, Daniela Petry Pioto⁷, Claudio Len⁸, Rogerio do Prado⁷ and Maria Terreri⁸, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Unifesp, São Paulo, Brazil
Background/Purpose: Childhood-onset Systemic lupus erythematosus (cSLE) is an inflammatory autoimmune disease known for its complex and variable clinical presentation and disease course. Its severity may…
Abstract Number: 1393 • ACR Convergence 2021
All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
Helen Keen¹, Warren Raymond², Susan Lester³, David Preen², Charles Inderjeeth⁴, Catherine Hill⁵ and Johannes Nossent², ¹University of Western Australia, Daglish, Australia, ²University of Western Australia, Perth, Australia, ³Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴University of Western Australia, Nedlands, Perth, Australia, ⁵Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Giant Cell Arteritis (GCA) is the most common primary vasculitis in high income countries and ischemic complications of GCA include blindness and stroke. The…
Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0851 • ACR Convergence 2021
Application of a Modified Recursive Feature Elimination Machine Learning Algorithm to Select Predictors of Mortality in Those with and Without Osteoarthritis
Siyeon Kim¹, Siqi Xiang¹, Liubov Arbeeva¹, Carolina Alvarez¹, Amanda Nelson¹, Yvonne Golightly¹, Leigh Callahan², Michael Kosorok¹ and Becki Cleveland³, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Radiographic osteoarthritis (rOA) and joint symptoms at the knee and hip are predictors of mortality. However, questions remain about the nature of the relationship…
Abstract Number: 1427 • ACR Convergence 2021
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sophie Dell’Aniello², Sofia Pedro³, Kaleb Michaud⁴ and Samy Suissa⁵, ¹University of Nebraska Medical Center, Bellevue, NE, ²Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada
Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
Abstract Number: 0246 • ACR Convergence 2021
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Betul Sozeri¹, Kenan Barut², Erdal Atalay³, Aysenur Pac Kisaarslan⁴, Semanur Ozdel⁵, Ozge Altug⁶, Ferhat Demir¹, Balahan Makay⁷, Nuray Aktay Ayaz⁸, Ersen Acar⁹, Fatih Haslak², Erdal Sag¹⁰, Mehmet YILDIZ², Ummusen Kaya Akca¹⁰, Amra Adrovic², Yelda Bilginer¹⁰, Hakan Poyrazoglu¹¹, Erbil Unsal⁷, Ozgur Kasapcopur¹² and Seza Ozen³, ¹University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ³Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey, ⁴Erciyes University Medical Faculty, Pediatric Rheumatology, Kayeri, Turkey, ⁵Ankara Dr.Sami Ulus Gynecology and Pediatrics Research and Training Hospital, Pediatric Rheumatology, Ankara, Turkey, ⁶Dr Behcet Uz Children's Hospital, Pediatric Rheumatology, Izmir, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey, ⁸Istanbul University, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ⁹Novartis, Istanbul, Turkey, ¹⁰Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹¹Erciyes University Faculty of Medicine, Pediatric Rheumatology, Kayseri, Turkey, ¹²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…
Abstract Number: 0865 • ACR Convergence 2021
Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study
Rangi Kandane-Rathnayake¹, Vera Golder¹, Worawit Louthrenoo², YI-HSING CHEN³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, Sandra Navarra⁹, Leonid Zamora⁹, Zhanguo Li¹⁰, Yuan An¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹³, B.M.D.B. Basnayake¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Shereen Oon¹⁸, Sang-Cheol Bae¹⁹, Sean O’Neill²⁰, Fiona Goldblatt²¹, Kathryn Gibson²⁰, Kristine (Pek Ling) Ng²², Annie Law²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Michael Tee²⁶, DaeYoung Yu²⁷, Chetan Karyekar²⁸, Yoshiya Tanaka²⁹, C.S. Lau³⁰, Mandana Nikpour³¹, Alberta Hoi³² and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶University of Padjadjaran, Bandung, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹¹University of Malaya, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹³Peking University First Hospital, Beijing, China (People's Republic), ¹⁴Teaching (General) Hospital, Kandy, Sri Lanka, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Keio University, Tokyo, Japan, ¹⁷Div. Rheumatology, Keio University, Tokyo, Japan, ¹⁸Melbourne Health, Parkville, Australia, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Liverpool Hospital, Sydney, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²North Shore Hospital, Auckland, New Zealand, ²³Singapore General Hospital, Singapore, Singapore, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Counties Manukau Health, Auckland, New Zealand, ²⁶University of the Philippines, Quezon City, Philippines, ²⁷Janssen Asia Pacific, Seoul, Republic of Korea, ²⁸Janssen R&D, Spring House, PA, ²⁹University of Occupational and Environmental Health, Kitakyushu, Japan, ³⁰University of Hong Kong, Hong Kong, Hong Kong, ³¹University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is high compared to the general population. Attainment of the Lupus Low Disease Activity State (LLDAS)…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0937 • ACR Convergence 2021
Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease
Gino Chesini¹, Elizabeth Parrott¹, Lauren Fox¹, Jenna Beatty¹, Cassandra Effken¹, Na Yu¹, Florence Hosseini-Aslinia¹ and Megan Krause², ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas, Kansas City, KS
Background/Purpose: Inflammatory bowel disease (IBD) causes a wide range of symptomology frequently leading to co-management of disease activity between gastroenterologist and rheumatologists. Recently in efforts…
Abstract Number: 1561 • ACR Convergence 2021
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
Jennifer Santana Peralta de Heyaime, Teresandris Polanco Mora, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic
Background/Purpose: SARS-CoV-2 infection is caused by a new coronavirus. The World Health Organization (WHO) had information about the existence of this new virus on December…
Abstract Number: 0339 • ACR Convergence 2021
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
Anum Akhlaq¹ and Abdul Mannan Khan Minhas², ¹Orange Park Medical Center, Orange Park, FL, ²Forrest General Hospital, Hattiesburg
Background/Purpose: Important disparities in SLE patients persist based on their sex and racial/ethnic status. The aim of this study is to examine the trends in…
Abstract Number: 0954 • ACR Convergence 2021
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Zachary Wallace¹, Xiaoqing Fu², Claire Cook³, Yuqing Zhang⁴, John Stone⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Lexington, MA
Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].